onalespib

Onalespib is a synthetic, orally bioavailable small-molecule inhibitor of heat shock protein 90 (HSP90), a molecular chaperone involved in the maturation and stabilization of various client proteins critical for cell cycle control and signal transduction. By inhibiting HSP90, onalespib disrupts the function of multiple oncogenic proteins, leading to antineoplastic effects. It has been investigated primarily as an anticancer agent in several solid tumors, including non-small cell lung cancer, triple-negative breast cancer, prostate cancer, and glioblastoma. Onalespib was originally developed by Astex Therapeutics and further developed by Astex Pharmaceuticals (a subsidiary of Otsuka) and the National Cancer Institute[2][5][6][9].

Other names

AT13387AT-13387AT 13387onalespib